01—Abstract
Summary
Summary of the 10-Q filed April 24, 2024. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics Incorporated (DGX) reported its first quarter 2024 results, showing a modest increase in net revenues driven by its core Diagnostic Information Services (DIS) segment.
Despite a slight overall revenue growth of 1.5% to $2.37 billiona, operating income saw a marginal decline of 1.7% to $300 million, and net income attributable to Quest Diagnostics decreased by 3.9% to $194 million. This was reflected in diluted earnings per share, which fell to $1.72 from $1.78 in the prior year's comparable quarter. The company completed an acquisition of Lenco Diagnostic Laboratories for $111 million, contributing to the growth in its DIS segment, although overall revenue per requisition saw minimal change.
Management highlighted the ongoing 'Invigorate' program aimed at driving cost savings and productivity improvements, which is being leveraged to offset inflationary pressures and reimbursement challenges. Looking ahead, Quest Diagnostics maintains a strong liquidity position with significant borrowing capacity available.
02—Key points
Key Highlights
- Net revenues increased by 1.5% to $2.37 billion for the three months ended March 31, 2024, compared to $2.33 billion in the prior year.
- Operating income decreased by 1.7% to $300 million, and net income attributable to Quest Diagnostics declined by 3.9% to $194 million.
- Diluted earnings per share (EPS) were $1.72, a decrease from $1.78 in the first quarter of 2023.
- The company completed the acquisition of Lenco Diagnostic Laboratories for $111 million, adding to its Diagnostic Information Services (DIS) segment.
- Cost of services increased by 2.3% to $1.595 billion, primarily due to higher supplies, wages, and benefit costs, partially offset by cost savings from the Invigorate program.
- Net cash provided by operating activities significantly increased by $60 million to $154 million, driven by lower performance-based compensation payments and the timing of income tax payments.
- Quest Diagnostics has $1.0 billion remaining under its share repurchase authorization and declared a quarterly cash dividend of $0.75 per common share.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Quest Diagnostics Inc kept $0.08.
- Revenue$2.37B100.0%
- Cost of revenue−$1.59B67.4%
- Gross profit$771.0M32.6%
- Operating costs−$471.0M19.9%
- Operating income$300.0M12.7%
- Interest, other & tax−$106.0M4.5%
- Net income$194.0M8.2%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed April 24, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $2.37B$2.33B | +1.5% |
| Cost of Revenue | $1.59B$1.56B | +2.2% |
| Gross Profit | $771.00M$771.00M | 0.0% |
| SG&A Expenses | $440.00M$439.00M | +0.2% |
| Operating Expenses | $2.07B$2.03B | +2.0% |
| Operating Income | $300.00M$305.00M | −1.6% |
| Interest Expense | $49.00M$37.00M | +32.4% |
| Net Income | $194.00M$202.00M | −4.0% |
| EPS (Basic) | $1.74$1.80 | −3.3% |
| EPS (Diluted) | $1.72$1.78 | −3.4% |
| Shares Outstanding (Basic) | 111.00M112.00M | −0.9% |
| Shares Outstanding (Diluted) | 112.00M113.00M | −0.9% |
05—Questions
Frequently Asked Questions
How did Quest Diagnostics' revenue perform in the first quarter of 2024?
Quest Diagnostics reported a 1.5% increase in net revenues to $2.37 billion for the three months ended March 31, 2024, compared to $2.33 billion in the same period of 2023. The Diagnostic Information Services (DIS) segment, which represents over 95% of revenues, saw a 1.7% increase.
What is the impact of the Invigorate program on the company's financials?
The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to offset inflationary pressures and reimbursement challenges. For the first quarter of 2024, the company incurred $17 million in pre-tax charges related to restructuring and integration activities, including employee separation costs, which are part of the ongoing efforts under this program.
How did the company's profitability change year-over-year?
Operating income decreased by 1.7% to $300 million, and net income attributable to Quest Diagnostics declined by 3.9% to $194 million. This resulted in diluted earnings per share falling to $1.72 from $1.78 in the prior year's first quarter.
What is the company's current cash flow situation?
Net cash provided by operating activities saw a substantial increase of $60 million to $154 million for the three months ended March 31, 2024, compared to the prior year. This improvement was attributed to lower performance-based compensation payments and the timing of income tax payments.
06—Continue